Allogeneic Transplantation Clinical Trial
Official title:
Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation
To look at the effect of a recipient's ancestry and socio-economic status on their choice of bone marrow transplantation donor cells and their chance of receiving genetically similar (allogeneic) bone marrow cells versus cells that are not genetically similar (allograft).
Primary Objectives To prospectively evaluate graft options and choice of donor by patient ancestry and SES for allograft candidates at MDACC. Secondary Objectives - To prospectively evaluate time to transplant for allograft candidates at MDACC. - To evaluate treatment-related mortality for allograft candidates at MDACC. - To assess overall survival for allograft candidates at MDACC. - To prospectively evaluate receipt of preferred unrelated donor for allograft recipients at MDACC. - To evaluate receipt of an optimal graft for allograft recipients at MDACC. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01440556 -
Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma
|
N/A | |
| Unknown status |
NCT00460447 -
Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00129155 -
MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
|
Phase 2 | |
| Recruiting |
NCT05612789 -
Improve Outcomes for Older Allogeneic Transplant Recipients
|
N/A |